The present invention relates to
antibody conjugates which are particularly suitable for targeting cells expressing PTK7, in particular
tumor cells. An
antibody conjugate according to the present invention has structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an
antibody capable of targeting a tumor expressing PTK7; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w '-wherein G is a
monosaccharide, j is an integer in the range of 0 to 10, S is a
sugar or a
sugar derivative, GlcNAc is N-
acetylglucosamine, and Fuc is
fucose, w is 0 or 1, w' is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an
anthracycline, a
camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a
maytansinoid, an aurestatin,
eribulin, a BCL-XL inhibitor, a
miscanthus semiaquilaria, a KSP inhibitor, a TLR
agonist, an indolo-
benzodiazepine dimer or a pyrrolo-
benzodiazepine dimer (PBD), and an analog or
prodrug thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said
antibody conjugate of structure (1) and to the use of said
antibody conjugate of structure (1).